Melisa Wilson, ARNP

Melisa Wilson , ARNP

Advanced Practitioner Provider Director

Heart, Lung and Vascular

Melisa Wilson

Overview

Melisa Wilson, APRN, ACNP-BC, is a board-certified advanced practice registered nurse with more than 10 years of clinical experience. A native of Mt. Vernon, NY, she earned her undergraduate and advanced nursing degrees at the University of Florida and has worked in pulmonary and cardiology specialty practices since 2006. Melisa works closely with Dr. James Tarver to treat and educate patients with pulmonary hypertension, as well as cardiovascular patients in emergency, inpatient and outpatient settings. In 2015, Melisa was the recipient of the Pulmonary Hypertension Association's Periwinkle Pioneer Award, presented to practitioners responsible for advancing care for pulmonary hypertension patients and helping to change the history of the disease.

Articles

Practical management of oral treprostinil in patients with pulmonary arterial hypertension: Lessons from ADAPT, EXPEDITE, and expert consensus

RESPIRATORY MEDICINE

2024

Why Living with Pulmonary Arterial Hypertension Requires a Holistic Approach: A Patient and Clinician Perspective

PULMONARY THERAPY

2023

Clinical application of risk assessment in PAH: Expert center APRN recommendations

Pulmonary circulation

2022

An expert panel Delphi consensus statement on the use of palliative care in the management of patients with pulmonary arterial hypertension

Pulmonary circulation

2022

Current clinical utilization of risk assessment tools in pulmonary arterial hypertension: a descriptive survey of facilitation strategies, patterns, and barriers to use in the United States

PULMONARY CIRCULATION

2020

More Publication Information

Education & Training

Education

Duke School of Nursing

Associated Clinical Trials

NCT04811092

HYPERION A Phase 3, Randomized, Doubleblind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial
Hypertension (PAH) Therapy in Newly Diagnosed Intermediate-and High-risk PAH Patients

Icon for trial | A011-13 HYPERION A Phase 3, Randomized, Doubleblind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate-and High-risk PAH Patients

This study is currently enrolling.

Pulmonary arterial hypertension (PAH) is a disease affecting the blood vessels of the lungs. PAH leads to increased pressure in the blood vessels of the lungs which further leads to straining of the right side of the heart. You ...